Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

Trial Profile

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Molindone (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms CHIME 2
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2017 According to a Supernus Pharmaceuticals media release, the company expects enrollment to continue through mid-2018.
    • 13 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 28 Feb 2017 According to a Supernus Pharmaceuticals media release, the company has received FDA approval for revisions to the Phase III protocols (this study and CTP 250895), which are expected to improve patient retention during the screening period and in turn improve patient enrollment. Enrollment is expected to continue through 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top